The nation of Zimbabwe has turned down a major US healthcare agreement worth $367m (272 million pounds) spanning five years over Washington's request for sensitive biological samples.
This rejection became public after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
An official spokesperson has since clarified that the United States was seeking genetic material for research and profit but refused to share the benefits from any future medical innovations.
"We will now turn to the difficult and regrettable process of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided more than $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further dialogue to find a agreement agreeable to both sides so the country's vital HIV treatment initiative can proceed.
Wider Implications
This rejection follows a similar case in Kenya, where a high court blocked a similar health funding agreement after legal challenges were filed about the security of Kenyans' medical information.
After resuming the presidency last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump claimed its spending was "inefficient" and his administration was seeking government-to-government agreements to enhance openness and accountability.
According to reports, 16 nations in Africa have to date agreed to similar agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership could have provided immense advantages for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information indefinitely, with no equivalent assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"In essence, our country would supply the raw materials for medical research without any certainty that the end products would be available to our citizens if a new pandemic emerge."
Sovereignty and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were undermining systems already established through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to deal with future pandemics.
"This framework is intended to guarantee that when a country contributes its data, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome continued dialogue with our American counterparts on how future co-operation might be designed in a way that respects the independence and interests of both nations."
Health Experts Reaction
A leading public health body stated it acknowledged the government's concerns, but suggested that negotiations should continue considering a large portion of the country's Aids initiatives depended on external financing.
"Where technical issues exist, including those relating to information security or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," the group added.
This impasse highlights the complex challenges between accepting vital international aid and safeguarding national sovereignty in an ever more data-driven world.